

## **Product datasheet for SR312923**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

# **SLC19A3 Human siRNA Oligo Duplex (Locus ID 80704)**

### **Product data:**

**Product Type:** siRNA Oligo Duplexes

Purity: HPLC purified

Quality Control: Tested by ESI-MS

Sequences: Available with shipment

**Stability:** One year from date of shipment when stored at -20°C.

# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final

conc. 10 nM).

**Note:** Single siRNA duplex (10nmol) can be ordered.

**RefSeq:** <u>NM 025243</u>

UniProt ID: Q9BZV2

**Synonyms:** BBGD; THMD2; thTr-2; THTR2

Components: SLC19A3 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 80704)

Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol

Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml

**Summary:** This gene encodes a ubiquitously expressed transmembrane thiamine transporter that lacks

folate transport activity. Mutations in this gene cause biotin-responsive basal ganglia disease

(BBGD); a recessive disorder manifested in childhood that progresses to chronic

encephalopathy, dystonia, quadriparesis, and death if untreated. Patients with BBGD have bilateral necrosis in the head of the caudate nucleus and in the putamen. Administration of

high doses of biotin in the early progression of the disorder eliminates pathological


symptoms while delayed treatment results in residual paraparesis, mild cognitive disability, or

dystonia. Administration of thiamine is ineffective in the treatment of this disorder.

Experiments have failed to show that this protein can transport biotin. Mutations in this gene

also cause a Wernicke's-like encephalopathy.[provided by RefSeq, Jan 2010]







# Performance Guaranteed:

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).